for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Incyte Corporation

INCY.O

Latest Trade

94.48USD

Change

0.49(+0.52%)

Volume

941,452

Today's Range

93.36

 - 

94.85

52 Week Range

57.00

 - 

95.45

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
93.99
Open
94.54
Volume
941,452
3M AVG Volume
23.67
Today's High
94.85
Today's Low
93.36
52 Week High
95.45
52 Week Low
57.00
Shares Out (MIL)
215.40
Market Cap (MIL)
20,350.74
Forward P/E
33.59
Dividend (Yield %)
--

Next Event

Incyte Corp at JPMorgan Healthcare Conference

Latest Developments

More

Incyte Reports 2019 Third-Quarter Financial Results

Incyte Announces First Patient Treated In Phase 3 Clinical Trial Program Evaluating Ruxolitinib Cream In Patients With Vitiligo

Lilly Announces Top-Line Phase 3 Results For Oral JAK Inhibitor Baricitinib, In Combination With Topical Corticosteroids In Adult Patients With Moderate To Severe Atopic Dermatitis

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Industry

Biotechnology & Drugs

Contact Info

1801 Augustine Cut off

+1.302.4986700

https://www.incyte.com/

Executive Leadership

Herve Hoppenot

Chairman of the Board, President, Chief Executive Officer

Christiana Stamoulis

Chief Financial Officer, Executive Vice President

Dashyant Dhanak

Executive Vice President, Chief Scientific Officer

Maria E. Pasquale

Executive Vice President, General Counsel

Paula J. Swain

Executive Vice President - Human Resources

Key Stats

2.22 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

1.1K

2017

1.5K

2018

1.9K

2019(E)

2.2K
EPS (USD)

2016

0.540

2017

-1.530

2018

1.040

2019(E)

2.798
Price To Earnings (TTM)
50.68
Price To Sales (TTM)
9.66
Price To Book (MRQ)
8.40
Price To Cash Flow (TTM)
44.20
Total Debt To Equity (MRQ)
2.09
LT Debt To Equity (MRQ)
2.06
Return on Investment (TTM)
16.70
Return on Equity (TTM)
14.12

Latest News

Latest News

Incyte unlawfully marketed cancer drug Jakafi says whistleblower lawsuit

Biopharmaceutical company Incyte Corp has engaged in a series of unlawful marketing and kickback schemes aimed at promoting the sale of its blockbuster bone marrow cancer drug Jakafi, a newly unsealed whistleblower lawsuit alleges.

BRIEF-FDA Approves Jakafi For The Treatment Of Patients With Acute Graft-Versus-Host Disease

* FDA APPROVES JAKAFI® (RUXOLITINIB) FOR THE TREATMENT OF PATIENTS WITH ACUTE GRAFT-VERSUS-HOST DISEASE

Incyte's Jakafi gets FDA approval to treat Graft vs Host Disease

The U.S. Food and Drug Administration on Friday approved Incyte Corp's treatment for acute Graft versus Host disease (GvHD), an inflammatory response by the immune system after a bone marrow transplant.

Incyte's Jakafi wins FDA nod to treat complication of stem cell transplant

The U.S. Food and Drug Administration on Friday approved Incyte Corp's treatment for acute graft-versus-host disease, a complication from stem cell transplant.

Incyte loses trade-secret case against Flexus over cancer drug

A Delaware state court jury has rejected pharmaceutical company Incyte Corp's claims that rival Flexus Biosciences Inc was unjustly enriched by stealing cancer drug research trade secrets from it before Bristol-Myers Squibb Co acquired Flexus in 2015.

BRIEF-Incyte's Mid-stage Geometry Mono-1 Trial Of Investigational Medicine Capmatinib Shows Positive Results

* PHASE 2 GEOMETRY MONO-1 TRIAL OF INVESTIGATIONAL MEDICINE CAPMATINIB SHOWS POSITIVE RESULTS IN PATIENTS WITH MET-MUTATED ADVANCED NSCLC

FDA approves lower dose of Lilly-Incyte arthritis drug

The U.S. Food and Drug Administration on Friday approved the lower dose of a rheumatoid arthritis drug developed by Eli Lilly and Incyte Corp, but declined to approve its higher and more lucrative dose.

FDA approves lower dose of Lilly-Incyte arthritis drug

The U.S. Food and Drug Administration on Friday approved the lower dose of a rheumatoid arthritis drug developed by Eli Lilly and Incyte Corp, but declined to approve its higher and more lucrative dose.

BRIEF-Incyte Reports Q1 Loss Of $0.19 Per Share

* INCYTE REPORTS 2018 FIRST-QUARTER FINANCIAL RESULTS AND UPDATES ON KEY CLINICAL PROGRAMS

FDA panel against higher dose of Lilly-Incyte arthritis drug

An arthritis drug developed by Eli Lilly & Co and Incyte Corp should not be approved at a 4-milligram dose, advisers to the U.S. FDA voted on Monday, in a setback to the drugmakers that were counting on the treatment as a future blockbuster.

BRIEF-Immunovaccine And Incyte Expand Clinical Collaboration

* IMMUNOVACCINE AND INCYTE EXPAND CLINICAL COLLABORATION EVALUATING COMBINATION IMMUNOTHERAPIES IN ADVANCED RECURRENT OVARIAN CANCER

FDA panel votes against approving higher dose of Lilly-Incyte arthritis drug

A U.S. FDA advisory committee voted 10-to-5 on Monday against approving a higher dose of a rheumatoid arthritis drug developed by Eli Lilly & Co and Incyte Corp, but recommended that it be approved in a lower dose.

UPDATE 2-Incyte tumbles after combo therapy with Merck fails study

Incyte Corp's shares sank more than 20 percent on Friday after its experimental cancer drug failed to bolster the effectiveness of Merck & Co's blockbuster Keytruda to treat skin cancer patients.

Incyte, Merck melanoma combo therapy fails study, shares slide

Incyte Corp said on Friday an independent committee concluded that its drug for a type of skin cancer in combination with Merck & Co's Keytruda failed to meet the main goal in a late-stage study.

BRIEF-Incyte, Merck Provide Update On Phase 3 Study

* INCYTE AND MERCK PROVIDE UPDATE ON PHASE 3 STUDY OF EPACADOSTAT IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA

BRIEF-Incyte CEO Hervé Hoppenot's 2017 Total Compensation Was $16.1 Mln Vs $11.8 Mln

* INCYTE CORP - CEO HERVÉ HOPPENOT'S 2017 TOTAL COMPENSATION WAS $16.1 MILLION VERSUS $11.8 MILLION - SEC FILING Source text: (http://bit.ly/2GsaYcC) Further company coverage:

BRIEF-Incyte Corp Q4 Loss Per Share $0.71

* INCYTE REPORTS 2017 FOURTH-QUARTER AND YEAR-END FINANCIAL RESULTS, PROVIDES 2018 FINANCIAL GUIDANCE AND UPDATES ON KEY CLINICAL PROGRAMS

BRIEF-Incyte Updates Conference Call Time To Report Fourth Quarter And Year-End Financial Results

* INCYTE UPDATES CONFERENCE CALL TIME TO REPORT FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS Source text for Eikon: Further company coverage:

BRIEF-Syros Pharmaceuticals Enters Amendment To Stock Purchase Agreement With Incyte

* SYROS PHARMACEUTICALS - ON JAN 31, ENTERED AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT WITH INCYTE TO FACILITATE PRIVATE PLACEMENT - SEC FILING

BRIEF-Incyte Corp Recommends Shareholders Reject Mini-Tender Offer By TRC Capital

* INCYTE CORPORATION RECOMMENDS SHAREHOLDERS REJECT MINI-TENDER OFFER BY TRC CAPITAL CORPORATION

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up